|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL3RA |
Gene summary for IL3RA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL3RA | Gene ID | 3563 |
| Gene name | interleukin 3 receptor subunit alpha | |
| Gene Alias | CD123 | |
| Cytomap | X | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | P26951 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3563 | IL3RA | HTA11_347_2000001011 | Human | Colorectum | AD | 7.16e-11 | 4.25e-01 | -0.1954 |
| 3563 | IL3RA | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.72e-03 | 3.66e-01 | -0.1207 |
| 3563 | IL3RA | HTA11_696_2000001011 | Human | Colorectum | AD | 2.65e-15 | 3.95e-01 | -0.1464 |
| 3563 | IL3RA | HTA11_866_2000001011 | Human | Colorectum | AD | 1.70e-07 | 3.05e-01 | -0.1001 |
| 3563 | IL3RA | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.85e-11 | 5.06e-01 | -0.059 |
| 3563 | IL3RA | HTA11_546_2000001011 | Human | Colorectum | AD | 1.95e-04 | 3.59e-01 | -0.0842 |
| 3563 | IL3RA | HTA11_866_3004761011 | Human | Colorectum | AD | 4.78e-02 | 1.74e-01 | 0.096 |
| 3563 | IL3RA | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.81e-03 | 3.28e-01 | 0.0338 |
| 3563 | IL3RA | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.72e-07 | 3.18e-01 | 0.0674 |
| 3563 | IL3RA | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.39e-02 | 6.79e-01 | 0.3487 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | CRC |  |
| Stomach | GC |  |
| Stomach | CAG with IM |  |
| Stomach | CSG |  |
| Stomach | CAG |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL3RA | SNV | Missense_Mutation | rs760003424 | c.914N>A | p.Arg305Gln | p.R305Q | P26951 | protein_coding | tolerated(0.43) | benign(0.132) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
| IL3RA | SNV | Missense_Mutation | c.628N>G | p.Pro210Ala | p.P210A | P26951 | protein_coding | tolerated(0.44) | probably_damaging(0.998) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
| IL3RA | SNV | Missense_Mutation | rs766258222 | c.328C>G | p.Leu110Val | p.L110V | P26951 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| IL3RA | SNV | Missense_Mutation | rs753774133 | c.146A>G | p.Asp49Gly | p.D49G | P26951 | protein_coding | tolerated(0.44) | benign(0) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| IL3RA | SNV | Missense_Mutation | novel | c.221C>A | p.Ser74Tyr | p.S74Y | P26951 | protein_coding | tolerated(0.07) | possibly_damaging(0.907) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IL3RA | SNV | Missense_Mutation | novel | c.879N>G | p.Cys293Trp | p.C293W | P26951 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| IL3RA | SNV | Missense_Mutation | c.81N>G | p.Ile27Met | p.I27M | P26951 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
| IL3RA | SNV | Missense_Mutation | c.886N>C | p.Glu296Gln | p.E296Q | P26951 | protein_coding | tolerated(0.11) | benign(0.425) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| IL3RA | SNV | Missense_Mutation | novel | c.35N>A | p.Ala12Asp | p.A12D | P26951 | protein_coding | deleterious(0.01) | benign(0.129) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IL3RA | SNV | Missense_Mutation | novel | c.818N>C | p.Arg273Thr | p.R273T | P26951 | protein_coding | deleterious(0.01) | possibly_damaging(0.766) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Flotetuzumab | FLOTETUZUMAB | ||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | MGD006 | FLOTETUZUMAB | ||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | 178101691 | ||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | IL-3 | 8910323 | ||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | 4SCAR19 and 4SCAR123 | |||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | JNJ-63709178 | |||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CSL-362-AML | |||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | EPO | EPOETIN ALFA | 8910323 | |
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CSL 360 | |||
| 3563 | IL3RA | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CAR-T cells targeting CD123 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |